更新于：2024-12-12
Norfloxacin
诺氟沙星
更新于：2024-12-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1984-02-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H18FN3O3 |
InChIKeyOGJPXUAPXNRGGI-UHFFFAOYSA-N |
CAS号70458-96-7 |
关联
55
项与 诺氟沙星 相关的临床试验诺氟沙星胶囊（0.1g）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
诺氟沙星胶囊在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹生物等效性试验研究方案
诺氟沙星胶囊在健康受试者中空腹状态下的单中心、随机、开放、两制剂、单剂量、双周期、两序列、双交叉生物等效性试验研究方案
100 项与 诺氟沙星 相关的临床结果
登录后查看更多信息
100 项与 诺氟沙星 相关的转化医学
登录后查看更多信息
100 项与 诺氟沙星 相关的专利（医药）
登录后查看更多信息
5,660
项与 诺氟沙星 相关的文献（医药）2025-03-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Electro-activated peroxymonosulfate based on hollow cubic skeleton nanoflower cathode catalyst MoSe2/cubic nanocage (CNC) for enhanced degradation of norfloxacin: Performance, mechanism, degradation pathways and toxicity
Article
作者: Fan, Zhirui ; Song, Peipei ; Liu, Jin
Recently, antibiotic wastewater pollution has become increasingly serious. In this study, a novel hollow cubic framework self-supported nanoflower-like cathode catalyst (MoSe2/CNC) based on Co Fe prussian blue analogues (CoFePBA)-derived cubic nanocage (CNC) loaded with MoSe2 was successfully prepared and utilized in an electro-activated peroxymonosulfate (PMS) system for norfloxacin (NOR) degradation. Benefit from the combined structures of MoSe2, MoC, and Co/FeNC, the electrocatalytic activity and specific surface area were greatly improved. The effects of catalyst dosage and ratio, current, PMS concentration, electrolyte type, pH, as well as initial concentration were comprehensively investigated. Under the optimal conditions, NOR and TOC removal reached 92.70% and 82.17%, respectively, which was superior to the previous studies. Additionally, ·O2- was proved to be the primary reactive species for NOR degradation.·Based on density functional theory (DFT) and intermediates analysis, NOR underwent substitution and ring-opening reactions in the piperazine ring, substitution of fluoride ions, and cleavage of the carboxyl group and tetrahydropyridine ring, ultimately converting into water, carbon dioxide, and inorganic ions. Moreover, toxicity assessment and seed germination experiments demonstrated that the toxicity of NOR and intermediates were strongly decreased by electro-activated PMS system based on MoSe2/CNC cathode. Overall, this study not only contributes to the evolution of efficient and sustainable wastewater purification technology, but also provides valuable insights into the degradation of antibiotic wastewater.
2025-02-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Specific smart sensing of electron-rich antibiotics or histidine improves the antenna effect, luminescence, and photodynamic sterilization capabilities of lanthanide polyoxometalates
Article
作者: Liang, Fu-Pei ; Zhu, Zhong-Hong ; Tang, Meng-Juan ; Li, Yun-Lan ; Zou, Hua-Hong ; Wang, Hai-Ling ; Qin, Wen-Wen
Excessive discharge of antibiotics seriously threatens human health and is thus a global public health problem. This highlights the urgent need to develop intelligent sensing materials for specific antibiotics that are highly visual, fast, convenient, and inexpensive. Herein, two reverse α-octamolybdate polyoxometalates (POMs; Mo8) were used to chelate lanthanide ions to obtain lanthanide POMs (LnPOMs; LnMo16; Ln = Eu, Sm, Tb, Gd) with highly sensitive smart photoresponses to specific antibiotics (ofloxacin [OFN], norfloxacin [NOR], enrofloxacin [ENR], and oxytetracycline [OTC]) and histidine (His) with luminescence turn-on. Specific antibiotics and His, which has an electron-rich structure, can efficiently enhance the antenna effect, thereby greatly improving the luminescence of EuMo16. Surprisingly, OFN and NOR both enhanced the luminescence of Eu(III) ions and Mo8, whereas ENR and OTC only enhanced the luminescence of Eu(III) ions, showing a differentiated sensitization effect. More notably, the combination of POMs and Ln(III) ions enhanced the ability of LnPOMs to produce reactive oxygen species under light irradiation, and these LnPOMs showed significant sterilization effects on Escherichia coli and Staphylococcus aureus. To our knowledge, this is the first time electron-rich antibiotics or amino acids were used to enhance the luminescence of LnPOMs, achieving luminescence-enhanced photoresponse to specific antibiotics and amino acids.
2025-02-01Infectious Diseases Now
Proposed macroscopic quality indicators of antimicrobial stewardship in primary care: An observational study
Article
作者: Bertrand, X ; Pouly, E ; Malinowski, L ; Slekovec, C
OBJECTIVE:
The objective of this study was to evaluate the ability of two macroscopic quality indicators to guide antibiotic stewardship strategies.
METHODS:
Setting: Bourgogne-Franche-Comté region (eight departments). Antibiotic reimbursement data, expressed in defined daily doses, were used to calculate two macroscopic quality indicators from 2015 to 2020. Urinary tract infection indicator: (fosfomycin + nitrofurantoin + pivmecillinam) / (ciprofloxacin + ofloxacin + norfloxacin) calculated in women aged 15 to 64. Indicator for ear, nose, throat and respiratory tract infections: (amoxicillin/ (amoxicillin-clavulanate + oral 3GC) calculated in children under 15 years of age.
RESULTS:
In 2020, global antibiotic consumption varied from 22.2 to 26.6 defined daily doses per 1000 inhabitants per day, depending on the department. The macroscopic quality indicators were lowest in the departments of Nièvre and Yonne. The scores for the urinary tract infection indicator were 0.55 and 0.74, respectively, while those for the ear, nose and throat and respiratory tract infection indicators were 1.85 and 2.12, respectively. Both scores continuously increased in all departments of the region during the survey, except in 2020 for the urinary tract infection indicator, due to a nitrofurantoin shortage.
CONCLUSION:
Even in departments with low antibiotic consumption, our macroscopic quality indicators help to identify antibiotic stewardship targets for the most common community-based infections,. They are easy to calculate from quantitative data without requiring any information on diagnosis. Complementarily to other indicators, they provide messages specifically addressed to general practitioners regarding population, molecules and diagnostic elements.
100 项与 诺氟沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 志贺氏菌感染 | 澳大利亚 | 2001-11-13 | |
| 胃肠道感染 | 澳大利亚 | 2001-11-13 | |
| 旅行者腹泻 | 澳大利亚 | 2001-11-13 | |
| 角膜溃疡 | 日本 | 1992-11-24 | |
| 睑缘炎 | 日本 | 1989-06-30 | |
| 睑缘炎 | 日本 | 1989-06-30 | |
| 结膜炎 | 日本 | 1989-06-30 | |
| 泪囊炎 | 日本 | 1989-06-30 | |
| 泪囊炎 | 日本 | 1989-06-30 | |
| 睑腺炎 | 日本 | 1989-06-30 | |
| 睑腺炎 | 日本 | 1989-06-30 | |
| 角膜炎 | 日本 | 1989-06-30 | |
| 淋病 | 中国 | 1986-01-01 | |
| 前列腺炎 | 中国 | 1986-01-01 | |
| 沙门氏菌感染 | 中国 | 1986-01-01 | |
| 伤寒 | 中国 | 1986-01-01 | |
| 泌尿道感染 | 中国 | 1986-01-01 | |
| 感染 | 日本 | 1984-02-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膀胱炎 | 临床3期 | - | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 49 | (Norflo Oro) | 衊築遞糧醖繭觸鏇壓繭(網窪淵餘鬱構鹽簾觸艱) = 鏇鏇壓膚壓範廠獵選淵 齋餘遞糧糧簾艱鏇簾憲 (繭蓋構獵願鬱淵鏇願築, 鑰淵餘衊襯衊廠網選繭 ~ 襯窪艱鬱選憲鏇選壓製) 更多 | - | 2022-03-28 | ||
(Placebo for Norflo Oro) | 衊築遞糧醖繭觸鏇壓繭(網窪淵餘鬱構鹽簾觸艱) = 憲壓積獵艱鹹鏇網膚鏇 齋餘遞糧糧簾艱鏇簾憲 (繭蓋構獵願鬱淵鏇願築, 築積蓋鏇構憲網糧鏇製 ~ 壓艱衊繭遞遞獵獵憲獵) 更多 | ||||||
N/A | 1,626 | 鹹鏇簾夢糧壓選簾窪獵(窪觸憲鏇鹽獵醖醖範鑰) = 網製糧顧鬱願廠壓憲壓 醖蓋簾鹽繭夢蓋窪鏇廠 (繭網鹹艱鏇鬱襯窪觸襯 ) 更多 | 不佳 | 2020-08-27 | |||
Placebo | - | ||||||
临床3期 | 291 | (顧築鏇顧夢衊艱窪繭壓) = 膚積遞膚鹽糧選簾觸夢 膚選選顧壓糧網製衊壓 (憲衊簾鹽壓願繭鏇餘繭 ) | - | 2018-12-01 | |||
Placebo | (顧築鏇顧夢衊艱窪繭壓) = 願築糧襯構壓積鑰膚觸 膚選選顧壓糧網製衊壓 (憲衊簾鹽壓願繭鏇餘繭 ) | ||||||
临床2期 | 9 | Placebo | 艱範鑰膚觸艱願觸繭餘(艱願鬱簾憲願襯窪廠糧) = 積構簾淵簾醖蓋遞蓋壓 衊獵網窪衊壓壓顧範憲 (醖窪蓋繭淵壓獵憲鑰窪 ) | - | 2010-12-01 | ||
N/A | - | Quinolones (Anaphylaxis patients) | 簾鹽夢觸鹽窪網範淵膚(鹹鹽淵選鏇鑰鑰鑰夢餘) = 壓廠繭醖鹹鹽齋糧鏇餘 蓋選蓋觸觸遞齋膚顧獵 (製鹹鬱廠蓋築網蓋蓋廠 ) | 积极 | 2010-02-01 | ||
Quinolones (Urticaria patients) | 簾鹽夢觸鹽窪網範淵膚(鹹鹽淵選鏇鑰鑰鑰夢餘) = 廠遞窪淵壓築夢廠構醖 蓋選蓋觸觸遞齋膚顧獵 (製鹹鬱廠蓋築網蓋蓋廠 ) | ||||||
N/A | - | - | 齋醖蓋簾構夢鹽衊願積(積膚顧積遞積糧鹹鑰觸) = 構構餘衊淵獵夢繭齋繭 夢糧蓋窪淵顧鑰壓淵襯 (鏇觸遞餘網齋網製糧鑰, 3.53) | - | 2002-12-01 | ||
齋醖蓋簾構夢鹽衊願積(積膚顧積遞積糧鹹鑰觸) = 鏇窪築憲鑰積鹹鬱壓觸 夢糧蓋窪淵顧鑰壓淵襯 (鏇觸遞餘網齋網製糧鑰, 1.18) | |||||||
临床3期 | 119 | 廠鏇選觸網蓋獵築鬱廠(製鹽襯築壓鏇遞構鬱獵) = 觸憲鑰膚築淵壓構齋範 艱醖鏇獵鑰鏇齋鹹齋製 (夢繭鹹簾鏇壓餘衊襯顧 ) 更多 | - | 1992-10-01 | |||
(Control) | (繭鏇糧顧簾襯繭壓膚鹽) = 顧夢膚鏇鬱夢網遞廠選 淵壓衊鑰艱憲積衊獵窪 (鹹製鏇鑰鹽鏇製窪齋獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用